Department of Gastroenterology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242-1009, USA.
Am J Gastroenterol. 2010 Apr;105(4):890-6. doi: 10.1038/ajg.2010.53. Epub 2010 Feb 23.
Although biofeedback therapy is effective in the short-term management of dyssynergic defecation, its long-term efficacy is unknown. Our aim was to compare the 1-year outcome of biofeedback (manometric-assisted pelvic relaxation and simulated defecation training) with standard therapy (diet, exercise, laxatives) in patients who completed 3 months of either therapy.
Stool diaries, visual analog scales (VASs), colonic transit, anorectal manometry, and balloon expulsion time were assessed at baseline, and at 1 year after each treatment. All subjects were seen at 3-month intervals and received reinforcement. Primary outcome measure (intention-to-treat analysis) was a change in the number of complete spontaneous bowel movements (CSBMs) per week. Secondary outcome measures included bowel symptoms, changes in dyssynergia, and anorectal function.
Of 44 eligible patients with dyssynergic defecation, 26 agreed to participate in the long-term study. All 13 subjects who received biofeedback, and 7 of 13 who received standard therapy, completed 1 year; 6 failed standard therapy. The number of CSBMs per week increased significantly (P<0.001) in the biofeedback group but not in the standard group. Dyssynergia pattern normalized (P<0.001), balloon expulsion time improved (P=0.0009), defecation index increased (P<0.001), and colonic transit time normalized (P=0.01) only in the biofeedback group.
Biofeedback therapy provided sustained improvement of bowel symptoms and anorectal function in constipated subjects with dyssynergic defecation, whereas standard therapy was largely ineffective.
尽管生物反馈疗法在协同性排便障碍的短期治疗中有效,但长期疗效尚不清楚。我们的目的是比较生物反馈(测压辅助骨盆松弛和模拟排便训练)与标准治疗(饮食、运动、泻药)在完成 3 个月治疗的患者中 1 年的结果。
在基线时以及每种治疗后 1 年评估粪便日记、视觉模拟量表(VAS)、结肠传输、肛门直肠测压和球囊排出时间。所有患者均在 3 个月间隔期就诊并接受强化治疗。主要疗效指标(意向治疗分析)是每周完全自发性排便次数(CSBMs)的变化。次要疗效指标包括肠道症状、协同性变化和肛门直肠功能。
在 44 名符合条件的协同性排便障碍患者中,26 名同意参与长期研究。所有接受生物反馈的 13 名患者中,有 13 名和接受标准治疗的 7 名患者完成了 1 年,6 名患者未完成标准治疗。每周 CSBMs 的数量在生物反馈组显著增加(P<0.001),而在标准组则没有增加。协同性模式正常化(P<0.001)、球囊排出时间改善(P=0.0009)、排便指数增加(P<0.001)和结肠传输时间正常化(P=0.01)仅在生物反馈组中发生。
生物反馈疗法为协同性排便障碍的便秘患者提供了持续的肠道症状和肛门直肠功能改善,而标准治疗则基本无效。